title: Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial.
abstract: BACKGROUND
  The purpose of this work was to describe the efficacy and safety of a telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) single-pill combination therapy in patients with moderate-severe hypertension (mean seated trough cuff systolic blood pressure [BP] ≥ 160 mmHg and diastolic BP ≥ 100 mmHg) in specific patient subpopulations.
  
  
  METHODS
  This was a planned analysis of a double-blind, multicenter, parallel-group trial that demonstrated the superiority of a single-pill combination of T80/H25 versus T80 monotherapy in terms of systolic BP change from baseline to week 7. Subpopulations included older (aged ≥ 65 years) versus younger, gender, race, hypertension severity, and prior antihypertensive therapy. Endpoints were change from baseline in mean seated trough cuff systolic and diastolic BP, proportion of patients achieving their BP goal (systolic/diastolic BP < 140/90 mmHg), and proportion of patients attaining systolic BP reductions of >30 mmHg and >40 mmHg.
  
  
  RESULTS
  Across all subgroups, the T80/H25 single-pill combination provided consistently greater systolic and diastolic BP reductions than T80 and more patients had systolic BP reductions of >30 mmHg. In the T80 and T80/H25 groups, BP control was achieved in 34.1% and 48.8% of men, 35.5% and 62.7% of women, 34.5% and 56.6% of Asians, 22.6% and 38.6% of blacks, 36.7% and 57.8% of whites, 36.9% and 57.5% of patients < 65 years, 29.3% and 49.3% ≥65 years, 44.2% and 66.2% of those with grade 2 hypertension, 20.4% and 39.4% of those with grade 3 hypertension, 38.9% and 53.2% of previously untreated patients, 38.1% and 62.5% of patients previously treated with one antihypertensive, and 29.7% and 48.9% of patients previously treated with two or more antihypertensive agents respectively. Treatment was generally well tolerated across the patient subgroups.
  
  
  CONCLUSIONS
  The T80/H25 single-pill combination provides consistent BP reductions and higher goal attainment rates versus T80 across a range of hypertensive patient subgroups, which are likely to have a positive impact on patients' cardiovascular risk.
authors: Shanghai Ruijin Hospital, Shanghai, People's Republic of China.
authors: Dingliang
authors: D
authors: Zhu
authors: Harold
authors: H
authors: Bays
authors: Pingjin
authors: P
authors: Gao
authors: Michaela
authors: M
authors: Mattheus
authors: Birgit
authors: B
authors: Voelker
authors: Luis M
authors: LM
authors: Ruilope
keywords: age; gender; grade 2 and 3 hypertension; hydrochlorothiazide; race; telmisartan
references: J Hum Hypertens. 2009 Dec;23(12):817-25
references: 19357698
references: J Clin Hypertens (Greenwich). 2011 Mar;13(3):146-54
references: 21366845
references: Hypertension. 2000 May;35(5):1025-30
references: 10818057
references: J Natl Med Assoc. 2006 Apr;98(4):618-26
references: 16623075
references: Am J Geriatr Cardiol. 2008 Jan-Feb;17(1):27-36
references: 18174757
references: Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48
references: 20150448
references: J Hypertens. 2007 Jun;25(6):1105-87
references: 17563527
references: Drugs. 2008;68(13):1877-99
references: 18729541
references: J Womens Health (Larchmt). 2008 Jul-Aug;17(6):931-8
references: 18681815
references: Postgrad Med. 2011 Jan;123(1):88-93
references: 21293088
references: Arch Intern Med. 1998 Apr 13;158(7):741-51
references: 9554680
references: Clin Ther. 2012 Jul;34(7):1613-24
references: 22717420
references: Kidney Int. 2002 Mar;61(3):1047-55
references: 11849460
references: Diabetol Metab Syndr. 2010 Jun 24;2(1):44
references: 20576135
references: Am J Epidemiol. 1985 Jan;121(1):11-8
references: 3964986
references: J Hypertens. 2010 Aug;28(8):1761-9
references: 20498618
references: J Hum Hypertens. 2009 Jan;23(1):4-11
references: 18615100
references: Circulation. 2008 Sep 23;118(13):1383-93
references: 18809808
references: Eur Heart J. 2011 Oct;32(20):2499-506
references: 21697169
references: Curr Med Res Opin. 2008 Sep;24(9):2617-26
references: 18687165
references: Int J Prev Med. 2010 Fall;1(4):217-9
references: 21566775
references: Int J Cardiol. 2010 Apr 1;140(1):73-81
references: 19059660
references: Hypertension. 2003 Dec;42(6):1206-52
references: 14656957
references: Hypertension. 2011 Oct;58(4):566-72
references: 21825231
references: J Card Fail. 1995 Jun;1(3):195-200
references: 9420651
references: Expert Opin Pharmacother. 2012 Feb;13(3):345-55
references: 22220825
references: Electrolyte Blood Press. 2010 Jun;8(1):51-7
references: 21468197